Alercon Nasal Spray - Nasal Spray Olopatadine 0.6% Nasal prep - 0.60% 1 120 Metered Sprays(s) / 120 Metered Sprays The ACME Laboratories Ltd. Indication: Allergic rhinitis Administration: Priming: Before initial use, prime Nasal Spray by releasing 5 sprays or until a fine mist appears. When Nasal Spray has not been used for more than 7 days, re-prime by releasing 2 sprays. Adult Dose: Nasal Seasonal allergic rhinitis Adult: As 0.6% spray: 2 sprays into each nostril bid. Child: 6-11 yr 1 spray into each nostril bid. Child Dose: Nasal Seasonal Allergic Rhinitis 12 years: 2 sprays each nostril twice daily. Contraindication: It is contraindicated incase of hypersensitivity to Olopatadine or to any component of the preparation. Mode of Action: Olopatadine is a relatively selective histamine H1-receptor antagonist which inhibits the release of histamine from mast cells and histamine-induced effects on conjunctival epithelial cells. It shares many of the pharmacologic effects of mast cell stabilisers. Precaution: Patients should be informed to avoid spraying Nasal Spray in their eyes. Patient w/ other nasal disease. Patient Counselling May impair ability to engage in activities requiring complete mental alertness and motor coordination (e.g. driving or operating machinery) after admin of the nasal spray. Nasal examinations should be performed periodically for signs of adverse effects on the nasal mucosa. Lactation: Unknown whether distributed in breast milk, caution advised Side Effect: >10% Bitter taste (12.8%; 1% pediatric),Respiratory epistaxis (3-25%) 1-10% Headache (4.4%),Depression (2%),Fatigue (1%),Somnolence (1%),Weight gain (1%),Epistaxis (3.2%; 5.7% pediatric),Upper respiratory tract infection (2.6% pediatric),Pharyngolaryngeal pain (2.2%),Postnasal drip (1.5%),Cough (1.4%),Urinary tract infection (1.2%),Upper respiratory tract infection in children (3%) <1% CPK elevation,Dry mouth,Anosmia,Hyposmia,Nasopharyngitis,Throat irritation,Influenza Interaction: May result in additive CNS depression w/ CNS depressants.